11
Orphan Designations
1
FDA Approvals
16
Rare Diseases
0
News Articles
| Disease | Drug(s) | Designation | Approved |
|---|---|---|---|
| B-cell chronic lymphocytic leukemia | umbralisib in combination with ublituximabumbralisibublituximab | Orphan Designation | - |
| Hodgkin's lymphoma, lymphocytic depletion | Ukoniq | Orphan Designation | - |
| MALT lymphoma | Ukoniqublituximab | Orphan Designation | - |
| adult neuronal ceroid lipofuscinosis | Ukoniq | Orphan Designation | - |
| adult pleomorphic rhabdomyosarcoma | Ukoniq | Orphan Designation | - |
| adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia | Ukoniq | Orphan Designation | - |
| adult-onset proximal spinal muscular atrophy, autosomal dominant | Ukoniq | Orphan Designation | - |
| diffuse large B-cell lymphoma | umbralisib in combination with ublituximab | Orphan Designation | - |
| extranodal nasal NK/T cell lymphoma | Ukoniqublituximab | Orphan Designation | - |
| follicular lymphoma | Ukoniq | Orphan Designation | - |
| multiple sclerosis | BRIUMVI | - | FDA Approved |
| mycosis fungoides | Ukoniqublituximab | Orphan Designation | - |
| neuromyelitis optica | ublituximab | Orphan Designation | - |
| nodal marginal zone B-cell lymphoma | Ukoniqublituximab | Orphan Designation | - |
| primary adult heart tumor | Ukoniq | Orphan Designation | - |
| splenic marginal zone lymphoma | Ukoniq | Orphan Designation | - |